Wearable Photoplethysmography for Non-invasive Hydration Assessment
1 other identifier
interventional
30
1 country
2
Brief Summary
Hydration status during exercise is often determined by measuring body mass change, fluid intake and urine output. However, obtaining these measurements can be an invasive, time-consuming process. Hydration status may be detectable by analyzing blood flow patterns of the superficial (just under the skin) blood vessels. Wearable devices are now abundant among the general population, and despite attempts from several groups, a hydration status metric based on noninvasive wearable device metrics has not been developed. With wearables, a light source connected to an optical sensor transmits and reflects light through the body. The light sensor detects absorption of the light based on wavelength measurements of the detected light. Absorption of specific wavelengths of light energy is dependent upon the amount of oxygenated blood in the vessels. When the vessels expand and relax, the amount of blood volume in the observed tissue increases and decreases potentially causing a shift in the photoplethysmography (PPG) wave detected by the wearable. The shift in the shape of the PPG wave may be detected in a way that indicates the relative change in tissue hydration levels. However, to our knowledge, no wrist worn device that utilizes PPG has been successfully able to predict hydration status. Therefore, this study aims to utilize photoplethysmography (PPG) technology in a wearable device to accomplish this approach to hydration monitoring.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2026
CompletedFirst Submitted
Initial submission to the registry
April 3, 2026
CompletedFirst Posted
Study publicly available on registry
April 9, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2026
April 9, 2026
April 1, 2026
5 months
April 3, 2026
April 3, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Wearable Sensr Data
photoplethysmogram (PPG) waveform data- optical signals obtained from photoplethysmography, which measure blood volume changes in the microvascular bed of tissue.
Continuous data collection over 24 hours from start of exercise trial through completion of Day 2 measurements.
Body Mass Change
Change in body mass during 60 min exercise bout and over 24 hours from baseline
Secondary Outcomes (12)
Urine Specific Gravity
Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory
Urine Volume
Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory
Urine Color
Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory
Sweat Rate
Throughout entire duration of 60 min exercise bout
Fluid Intake
documented by subject on provided log for 24 hours prior to exercise and experimental trials. Exercise bouts- DEH group restricted from fluid intake. EUH group fluid measured over duration of exercise bout (60 minutes).
- +7 more secondary outcomes
Study Arms (2)
Euhydrated Group
OTHERWater provided to account for sweat loss during exercise and to maintain hydration over the 24-hour period
Dehydrated Group
EXPERIMENTALFluid restriction during exercise and the remaining 24 hours
Interventions
Perform stationary cycling exercise in the laboratory for 2 30- minute bouts at a standardized exercise intensity (wattage) that elicits 50-80% heart rate max determined by equation (208-(70% of age))
Eligibility Criteria
You may qualify if:
- Study subject is 18-45 years of age, inclusive
- Subject is male or female
- If female, subject is not pregnant, planning to get pregnant, or currently breast feeding
- Subject is willing to avoid alcohol consumption 24 hours prior to visit(s)
- Able to speak, write, and read English
- Provision of written consent to participate
- Subject is not taking medication that may interfere with the study, as indicated on the general health questionnaire (GHQ)
- Subject has no health conditions that would prevent completion of the trial, as indicated on the GHQ
- Subject is willing to fast overnight (no food or beverage, only water, \~8- 10 hours)
- Subject is willing to refrain from vigorous exercise for 24 hours
- Subject is willing to eat the exact same food the day prior to each visit to the testing site
- Subject is willing to undergo fluid restriction to induce dehydration
- Subject is willing to wear a wrist worn wearable device for the duration of the study
You may not qualify if:
- Subject has participated or currently enrolled in a clinical trial within the past 30 days
- Subject has participated in any PepsiCo trial within the past 3 months
- Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk, as indicated on the GHQ
- Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.
- Subject has a health condition or is taking medication that can be worsened by fluid restriction, as indicated on the GHQ
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
PepsiCo R&D
Frisco, Texas, 75034, United States
PepsiCo R&D
Plano, Texas, 75024, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2026
First Posted
April 9, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
October 1, 2026
Last Updated
April 9, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share